Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11032 results:
[ Συντάκτης(Asc)] Τίτλος Τύπος Έτος
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Polyzos, S. A., Kountouras J., & Zavos C. (2010).  Adiponectin as a potential therapeutic agent for nonalcoholic steatohepatitis.. Hepatol Res. 40(4), 446-7.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Triantafyllou G. Α., & Mantzoros C. S. (2016).  Activin A and follistatin in patients with nonalcoholic fatty liver disease.. Metabolism. 65(10), 1550-8.
Polyzos, S. A., Kita M., & Avramidis A. (2007).  Thyroid nodules - stepwise diagnosis and management.. Hormones (Athens). 6(2), 101-19.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2011).  The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature.. J Clin Gastroenterol. 45(1), 50-4.
Polyzos, S. A., & Kountouras J. (2023).  Nonalcoholic fatty liver disease and Helicobacter pylori infection. Is it time to address this potential relationship?. Curr Vasc Pharmacol.
Polyzos, S. A., Makras P., Efstathiadou Z., & Anastasilakis A. D. (2015).  Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis.. Expert Opin Investig Drugs. 24(2), 145-57.
Polyzos, S. A., Kountouras J., Deretzi G., Zavos C., & Mantzoros C. S. (2012).  The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease.. Curr Mol Med. 12(1), 68-82.
Polyzos, S. A., & Kountouras J. (2020).  Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis.. Ann Hepatol. 19(5), 579-580.
Polyzos, S. A., Kountouras J., Shields K., & Mantzoros C. S. (2013).  Irisin: a renaissance in metabolism?. Metabolism. 62(8), 1037-44.
Polyzos, S. A., Goulis D. G., & Kountouras J. (2015).  Nonalcoholic fatty liver disease and polycystic ovary syndrome.. Ann Hepatol. 14(6), 941-3.
Polyzos, S. A., & Mantzoros C. S. (2023).  Sarcopenia: still in relative definition-penia and severe treatment-penia.. Metabolism. 155717.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z. A., Yavropoulou M. P., & Makras P. (2021).  Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations.. Maturitas. 147, 19-25.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2011).  The association between Helicobacter pylori infection and insulin resistance: a systematic review.. Helicobacter. 16(2), 79-88.
Polyzos, S. A., & Mantzoros C. S. (2015).  An update on the validity of irisin assays and the link between irisin and hepatic metabolism.. Metabolism. 64(9), 937-42.
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2012).  Comment on: Jeon et al. Helicobacter pylori Infection Is Associated With an Increased Rate of Diabetes. Diabetes Care 2012;35:520-525.. Diabetes Care. 35(7), e53; author reply e54.
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z. A., Makras P., Perakakis N., Kountouras J., et al. (2018).  Irisin in metabolic diseases.. Endocrine. 59(2), 260-274.
Polyzos, S. A., Anastasilakis A. D., & Terpos E. (2009).  Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid.. Support Care Cancer. 17(10), 1329-30.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Geladari E. V., & Mantzoros C. S. (2014).  Irisin in patients with nonalcoholic fatty liver disease.. Metabolism. 63(2), 207-17.
Polyzos, S. A., Kang E. Seok, Tsochatzis E. A., Kechagias S., Ekstedt M., Xanthakos S., et al. (2020).  Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name.. Metabolism. 113, 154413.
Polyzos, S. A., & Mantzoros C. S. (2022).  Metreleptin for the treatment of lipodystrophy: leading the way among novel therapeutics for this unmet clinical need.. Curr Med Res Opin. 38(6), 885-888.
Polyzos, S. A., Kountouras J., Zafeiriadou E., Patsiaoura K., Katsiki E., Deretzi G., et al. (2011).  Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease.. J Renin Angiotensin Aldosterone Syst. 12(4), 498-503.
Polyzos, S. A., & Mantzoros C. S. (2016).  Nonalcoholic fatty future disease.. Metabolism. 65(8), 1007-16.
Polyzos, S. A., Kountouras J., Romiopoulos I., & Polymerou V. (2013).  Serum visfatin in nonalcoholic fatty liver disease.. Ann Hepatol. 13(1), 150-1.
Polyzos, S. A., & Kountouras J. (2019).  Helicobacter pylori Infection: One More Contributor to Nonalcoholic Fatty Liver Disease Pathophysiology.. J Clin Gastroenterol.
Polyzos, S. A., & Terpos E. (2018).  Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis.. Endocrine. 62(2), 487-489.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές